These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2943553)

  • 1. Suppression of complement-mediated vascular injury at Arthus reaction sites by complement inhibitors.
    Asghar SS; Dingemans KP; Kammeijer A; Faber WR; Abdel Mawla MY
    Complement; 1986; 3(1):40-8. PubMed ID: 2943553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of vascular injury at the Arthus reaction site by a complement inhibitor, 5,5',5''-(1,3,6-naphthalene-triyl-tris[sulfonylimino])-tris (1,3-benzene disulfonic acid) hexasodium salt.
    Abdel Mawla MY; Dingemans KP; Amer M; Venneker GT; van Meegen M; Asghar SS
    Complement Inflamm; 1991; 8(1):50-9. PubMed ID: 1828755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P-selectin requirement for neutrophil accumulation and injury in the direct passive Arthus reaction.
    Santos LL; Huang XR; Berndt MC; Holdsworth SR
    Clin Exp Immunol; 1998 May; 112(2):281-6. PubMed ID: 9649192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of active Arthus reaction by colchicine.
    Miyachi Y; Danno K; Imamura S
    Br J Dermatol; 1981 Sep; 105(3):279-83. PubMed ID: 6456013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of cellular infiltration at the site of Arthus reaction by chlorpromazine. Use of a new area integration technique.
    Kammeyer A; Abdel Mawla MY; Oosterhoorn AD; Amer M; Asghar SS
    Int J Immunopharmacol; 1990; 12(6):685-90. PubMed ID: 2148738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STUDIES ON THE LOCALIZATION OF CIRCULATING ANTIGEN-ANTIBODY COMPLEXES AND OTHER MACROMOLECULES IN VESSELS. I. STRUCTURAL STUDIES.
    COCHRANE CG
    J Exp Med; 1963 Oct; 118(4):489-502. PubMed ID: 14067901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Arthus reaction in rodents: species-specific requirement of complement.
    Szalai AJ; Digerness SB; Agrawal A; Kearney JF; Bucy RP; Niwas S; Kilpatrick JM; Babu YS; Volanakis JE
    J Immunol; 2000 Jan; 164(1):463-8. PubMed ID: 10605043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disappearance of immunoglobulin and complement from the Arthus reaction and its relevance to studies of vasculitis in man.
    Cream JJ; Bryceson AD; Ryder G
    Br J Dermatol; 1971 Feb; 84(2):106-9. PubMed ID: 4100978
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeting complement in therapy.
    Kirschfink M
    Immunol Rev; 2001 Apr; 180():177-89. PubMed ID: 11414360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of immune-complex mediated dermal inflammation in rats following either oral or topical administration of a small molecule C5a receptor antagonist.
    Strachan AJ; Shiels IA; Reid RC; Fairlie DP; Taylor SM
    Br J Pharmacol; 2001 Dec; 134(8):1778-86. PubMed ID: 11739255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The possible role of membrane complement regulators in vasculitis.
    Daha MR
    Behring Inst Mitt; 1993 Aug; (92):184-90. PubMed ID: 7504449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BOUND COMPLEMENT AND IMMUNOLOGIC INJURY OF BLOOD VESSELS.
    WARD PA; COCHRANE CG
    J Exp Med; 1965 Feb; 121(2):215-34. PubMed ID: 14264268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic inhibition of the complement system. Y2K update.
    Asghar SS; Pasch MC
    Front Biosci; 2000 Sep; 5():E63-81. PubMed ID: 10966868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant soluble human complement receptor type 1 inhibits inflammation in the reversed passive arthus reaction in rats.
    Yeh CG; Marsh HC; Carson GR; Berman L; Concino MF; Scesney SM; Kuestner RE; Skibbens R; Donahue KA; Ip SH
    J Immunol; 1991 Jan; 146(1):250-6. PubMed ID: 1824590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of phenothiazine sulphonate and chlorophenothiazine sulphonate with the B-determinant of the third component of complement (C3).
    Asghar SS; Kammeijer A
    Mol Immunol; 1979 Feb; 16(2):117-21. PubMed ID: 87372
    [No Abstract]   [Full Text] [Related]  

  • 16. Accumulation of platelets at sites of antigen-antibody-mediated injury: a possible role for IgE antibody and mast cells.
    Kravis TC; Henson PM
    J Immunol; 1977 May; 118(5):1569-73. PubMed ID: 140191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human recombinant soluble decay accelerating factor inhibits complement activation in vitro and in vivo.
    Moran P; Beasley H; Gorrell A; Martin E; Gribling P; Fuchs H; Gillett N; Burton LE; Caras IW
    J Immunol; 1992 Sep; 149(5):1736-43. PubMed ID: 1380537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutrophil elicitation in the reverse passive Arthus reaction. Complement-dependent and -independent mast cell involvement.
    Ramos BF; Zhang Y; Jakschik BA
    J Immunol; 1994 Feb; 152(3):1380-4. PubMed ID: 8301139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presence of complement-fixing anti-endothelial cell antibodies in systemic lupus erythematosus.
    Cines DB; Lyss AP; Reeber M; Bina M; DeHoratius RJ
    J Clin Invest; 1984 Mar; 73(3):611-25. PubMed ID: 6368583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement proteins and complement inhibitors in Alzheimer's disease.
    McGeer PL; McGeer EG
    Res Immunol; 1992; 143(6):621-4. PubMed ID: 1455053
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.